Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
20,761,963
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
929,752
-
Shares change
-
+929,652
-
Total reported value, excl. options
-
$2,152,582
-
Value change
-
+$2,152,350
-
Number of buys
-
18
-
Price
-
$2.32
Significant Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) as of Q1 2023
19 filings reported holding CASI - CASI Pharmaceuticals, Inc. - Ordinary Shares as of Q1 2023.
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 929,752 shares
of 20,761,963 outstanding shares and own 4.48% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (257,618 shares), Wellington Shields Capital Management, LLC (180,143 shares), Wellington Shields & Co., LLC (139,315 shares), GEODE CAPITAL MANAGEMENT, LLC (98,133 shares), BlackRock Inc. (91,715 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (38,326 shares), STATE STREET CORP (35,555 shares), NORTHERN TRUST CORP (29,825 shares), FRANKLIN RESOURCES INC (24,923 shares), and RENAISSANCE TECHNOLOGIES LLC (13,100 shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.